Modulating the terminal unfolded protein response


Founded in 2014, OptiKira is advancing discoveries made by a team from The University of California, San Francisco and the University of Washington. Extensive research by our academic founders and others has defined the central role of the unfolded protein response (UPR) pathway in the progressive cell death which characterizes diseases such as pulmonary fibrosis, nonalcoholic steatohepatitis (NASH), diabetes, neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), cancer, and retinitis pigmentosa.



Read more on the development of our novel therapeutics.

Learn More →


Get to know our drug development experts.

Learn More →